These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 29691590)

  • 21. Metabolic reprogramming and epigenetic modifications in cancer: from the impacts and mechanisms to the treatment potential.
    Xu X; Peng Q; Jiang X; Tan S; Yang Y; Yang W; Han Y; Chen Y; Oyang L; Lin J; Xia L; Peng M; Wu N; Tang Y; Li J; Liao Q; Zhou Y
    Exp Mol Med; 2023 Jul; 55(7):1357-1370. PubMed ID: 37394582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cellular plasticity in reprogramming, rejuvenation and tumorigenesis: a pioneer TF perspective.
    Huyghe A; Trajkova A; Lavial F
    Trends Cell Biol; 2024 Mar; 34(3):255-267. PubMed ID: 37648593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. WNT-Regulated Transcriptional Enhancers and Stem Cell Plasticity.
    Mirzadeh Azad F; Atlasi Y
    Trends Cell Biol; 2021 Jul; 31(7):525-528. PubMed ID: 33775538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Silencing of the EPHB3 tumor-suppressor gene in human colorectal cancer through decommissioning of a transcriptional enhancer.
    Jägle S; Rönsch K; Timme S; Andrlová H; Bertrand M; Jäger M; Proske A; Schrempp M; Yousaf A; Michoel T; Zeiser R; Werner M; Lassmann S; Hecht A
    Proc Natl Acad Sci U S A; 2014 Apr; 111(13):4886-91. PubMed ID: 24707046
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reprogramming to developmental plasticity in cancer stem cells.
    O'Brien-Ball C; Biddle A
    Dev Biol; 2017 Oct; 430(2):266-274. PubMed ID: 28774727
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Directed Dedifferentiation Using Partial Reprogramming Induces Invasive Phenotype in Melanoma Cells.
    Knappe N; Novak D; Weina K; Bernhardt M; Reith M; Larribere L; Hölzel M; Tüting T; Gebhardt C; Umansky V; Utikal J
    Stem Cells; 2016 Apr; 34(4):832-46. PubMed ID: 26753613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cellular reprogramming and cancer development.
    Semi K; Matsuda Y; Ohnishi K; Yamada Y
    Int J Cancer; 2013 Mar; 132(6):1240-8. PubMed ID: 23180619
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concise Review: Reprogramming, Behind the Scenes: Noncanonical Neural Stem Cell Signaling Pathways Reveal New, Unseen Regulators of Tissue Plasticity With Therapeutic Implications.
    Poser SW; Chenoweth JG; Colantuoni C; Masjkur J; Chrousos G; Bornstein SR; McKay RD; Androutsellis-Theotokis A
    Stem Cells Transl Med; 2015 Nov; 4(11):1251-7. PubMed ID: 26371344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis.
    Roe JS; Hwang CI; Somerville TDD; Milazzo JP; Lee EJ; Da Silva B; Maiorino L; Tiriac H; Young CM; Miyabayashi K; Filippini D; Creighton B; Burkhart RA; Buscaglia JM; Kim EJ; Grem JL; Lazenby AJ; Grunkemeyer JA; Hollingsworth MA; Grandgenett PM; Egeblad M; Park Y; Tuveson DA; Vakoc CR
    Cell; 2017 Aug; 170(5):875-888.e20. PubMed ID: 28757253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer Plasticity: The Role of mRNA Translation.
    Lee LJ; Papadopoli D; Jewer M; Del Rincon S; Topisirovic I; Lawrence MG; Postovit LM
    Trends Cancer; 2021 Feb; 7(2):134-145. PubMed ID: 33067172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma.
    Falletta P; Sanchez-Del-Campo L; Chauhan J; Effern M; Kenyon A; Kershaw CJ; Siddaway R; Lisle R; Freter R; Daniels MJ; Lu X; Tüting T; Middleton M; Buffa FM; Willis AE; Pavitt G; Ronai ZA; Sauka-Spengler T; Hölzel M; Goding CR
    Genes Dev; 2017 Jan; 31(1):18-33. PubMed ID: 28096186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. p53 connects tumorigenesis and reprogramming to pluripotency.
    Tapia N; Schöler HR
    J Exp Med; 2010 Sep; 207(10):2045-8. PubMed ID: 20876313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cis-acting super-enhancer lncRNAs as biomarkers to early-stage breast cancer.
    Ropri AS; DeVaux RS; Eng J; Chittur SV; Herschkowitz JI
    Breast Cancer Res; 2021 Oct; 23(1):101. PubMed ID: 34717732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bcl11b and Atoh8 Coordinate Cellular Plasticity for Reprogramming and Transformation.
    Huang MF; Shoemaker R; Lee DF
    Cell Reprogram; 2022 Dec; 24(6):324-326. PubMed ID: 36409720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transcriptional landscape and clinical utility of enhancer RNAs for eRNA-targeted therapy in cancer.
    Zhang Z; Lee JH; Ruan H; Ye Y; Krakowiak J; Hu Q; Xiang Y; Gong J; Zhou B; Wang L; Lin C; Diao L; Mills GB; Li W; Han L
    Nat Commun; 2019 Oct; 10(1):4562. PubMed ID: 31594934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transcriptional dysregulation by aberrant enhancer activation and rewiring in cancer.
    Okabe A; Kaneda A
    Cancer Sci; 2021 Jun; 112(6):2081-2088. PubMed ID: 33728716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance.
    Bi M; Zhang Z; Jiang YZ; Xue P; Wang H; Lai Z; Fu X; De Angelis C; Gong Y; Gao Z; Ruan J; Jin VX; Marangoni E; Montaudon E; Glass CK; Li W; Huang TH; Shao ZM; Schiff R; Chen L; Liu Z
    Nat Cell Biol; 2020 Jun; 22(6):701-715. PubMed ID: 32424275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Context-Dependent Impact of RAS Oncogene Expression on Cellular Reprogramming to Pluripotency.
    Ferreirós A; Pedrosa P; Da Silva-Álvarez S; Triana-Martínez F; Vilas JM; Picallos-Rabina P; González P; Gómez M; Li H; García-Caballero T; González-Barcia M; Vidal A; Collado M
    Stem Cell Reports; 2019 May; 12(5):1099-1112. PubMed ID: 31056476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An epigenetic perspective on tumorigenesis: Loss of cell identity, enhancer switching, and NamiRNA network.
    Liang Y; Xu P; Zou Q; Luo H; Yu W
    Semin Cancer Biol; 2019 Aug; 57():1-9. PubMed ID: 30213688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancer malfunction in cancer.
    Herz HM; Hu D; Shilatifard A
    Mol Cell; 2014 Mar; 53(6):859-66. PubMed ID: 24656127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.